Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
In this update, Mr. Nathanielsz highlights the significant progress achieved during 2025 and outlines the Company’s ambitious plans for 2026.
-
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...
-
Tisento's global Phase 2b PRIZM study, which is evaluating zagociguat for the treatment of the rare mitochondrial disease MELAS, is fully enrolled
-
Herantis Pharma Plc – Company release Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Biomarker...
-
PridCor Therapeutics advances its SHIELD Long COVID study with a peer-reviewed publication and FDA confirmation of IND exemption.
-
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
-
SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- PolarityBio©, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous...
-
Our findings demonstrate that PRP exerts multifaceted effects specifically over the cancer associated fibroblasts (CAFs) population and tumor cells.
-
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
NeuExcell’s NXL-004, first in situ conversion gene therapy, shows promising safety and efficacy in 11 GBM patients at ESMO Asia 2025